摘要
伤害素/孤啡肽FQ肽受体(NOPR)是一种G蛋白偶联受体,以伤害素/孤儿FQ肽(N/OFQ)为内源性激动剂。它在神经系统以及在一些非神经组织中。其激活在椎管上有前感受作用,而在脊髓水平则在低剂量下产生伤害感受效应,在低剂量下产生抗伤害作用。高剂量。NOPR还参与情绪和血压调节,免疫调节,气道收缩,喂养,排尿,肠动力,学习和记忆。选择性NOPR激动剂临床测试为抗焦虑药和镇咳药,以及镇痛剂、抗抑郁药和治疗酒精成瘾的拮抗剂。两种NOPR放射性配体也在Hum中进行了测试。ANS作为神经显像剂。此外,部分激动剂SER100和N/OFQ已分别用于治疗充血性心力衰竭和膀胱过度活动。证据NOP与μ-阿片受体(MOPr)受体的相互作用已被开发用于使用NOPR/MOPr混合调节剂作为镇痛剂和治疗药物成瘾。这些药是开发出来的典型阿片类药物负债。在这篇综述中,我们概述了NOPR激动剂的结构-活性关系(SAR)的最新进展。
关键词: 伤害感受器、NOP受体配体、阿片类药物、结构-活性关系、G蛋白偶联受体、疼痛。
Current Medicinal Chemistry
Title:Nociceptin /Orphanin FQ Peptide (NOP) Receptor Modulators: An Update in Structure-Activity Relationships
Volume: 25 Issue: 20
关键词: 伤害感受器、NOP受体配体、阿片类药物、结构-活性关系、G蛋白偶联受体、疼痛。
摘要: Nociceptin /Orphanin FQ Peptide” receptor (NOPr) is a G-protein-coupled receptor with the nociceptin/orphanin FQ peptide (N/OFQ) as endogenous agonist. It is expressed in the nervous system as well as in some non-neural tissues. Its activation has pronociceptive effect at the supraspinal level, whereas at the spinal level it produces nociceptive effects at low doses and antinociceptive effects at higher doses. NOPr is also involved in mood and blood pressure regulation, immunoregulation, airway constriction, feeding, urination, bowel motility, learning and memory. Selective NOPr agonists have been tested clinically as anxiolytics and antitussives, and the antagonists as analgesics, antidepressants and in the treatment of alcohol addiction. Two NOPr radioligands have also been tested in humans as neuroimaging agents. Furthermore, the partial agonist peptide SER100 and N/OFQ have been used in clinical trials, respectively for congestive heart failure and overactive bladder. The evidence of interactions between NOP and μ-opioid receptor (MOPr) receptors has been exploited in the use of mixed NOPr/MOPr modulators as analgesics and in the treatment of drug addiction. These drugs are devoid of typical opioid liabilities. In this review, we outline the latest advances in the structure-activity relationships (SAR) of NOPr agonists and antagonists, with emphasis on affinity, activity, selectivity and pharmacokinetic features.
Export Options
About this article
Cite this article as:
Nociceptin /Orphanin FQ Peptide (NOP) Receptor Modulators: An Update in Structure-Activity Relationships, Current Medicinal Chemistry 2018; 25 (20) . https://dx.doi.org/10.2174/0929867325666180111095458
DOI https://dx.doi.org/10.2174/0929867325666180111095458 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Basis of Mineralocorticoid Receptor Action in the Nervous System
CNS & Neurological Disorders - Drug Targets High Throughput Screening for Colorectal Cancer Specific Compounds
Combinatorial Chemistry & High Throughput Screening Plasma Glucose Concentrations and Cardiac Hypertrophy in Essential Hypertension
Current Hypertension Reviews The Need for Physiologically Relevant Peroxisome Proliferator-Activated Receptor-gamma (PPAR-γ) Ligands
Endocrine, Metabolic & Immune Disorders - Drug Targets Using Extracellular Matrix-Derived Peptides to Alter the Microenvironment for Myocardial Repair
Current Vascular Pharmacology Cardiac and Pulmonary Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Metabolic Features Across the Female Life Span in Women with PCOS
Current Pharmaceutical Design Pleiotropic Effects of ARB in Metabolic Syndrome
Current Vascular Pharmacology Diabetes-induced Epigenetic Signature in Vascular Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Management Of Elderly Patients With Diffuse Large B-Cell Lymphomas
Anti-Cancer Agents in Medicinal Chemistry GPCR Drug Discovery: Novel Ligands for CNS Receptors
Recent Patents on CNS Drug Discovery (Discontinued) Modulators of Networks: Molecular Targets of Arterial Calcification Identified in Man and Mice
Current Pharmaceutical Design Alzheimer's Disease: Related Targets, Synthesis of Available Drugs, Bioactive Compounds Under Development and Promising Results Obtained from Multi-target Approaches
Current Drug Targets Vascular Endothelial Growth Factor Receptor 1, a Therapeutic Target in Cancer, Inflammation and Other Disorders
Current Medicinal Chemistry Neuropeptides as Therapeutic Approach to Autoimmune Diseases
Current Pharmaceutical Design Therapeutic Strategies Targeting Endothelial Function in Humans:Clinical Implications
Current Vascular Pharmacology Strategic Role of Nuclear Inositide Signalling in Myelodysplastic Syndromes Therapy
Mini-Reviews in Medicinal Chemistry Acute Cellular Oxygen Sensing in the Heart - A Role for Mitochondria?
Vascular Disease Prevention (Discontinued) Myocardial Perfusion SPECT Imaging in Patients after Percutaneous Coronary Intervention
Current Cardiology Reviews Alcohol and the Cardiovascular System: A Double-Edged Sword
Current Pharmaceutical Design